Aggregated News

Figure 3. Fundus of patient with retinitis pigmentosa, end stage (Pigment deposits are present all over the retina. Retinal vessels are very thin and optic disc is pale.) Hamel Orphanet Journal of Rare Diseases 2006 1:40 doi:10.1186/1750-1172-1-40 (Wikimedia)
Untitled Document

A blind woman in Texas is the first person to undergo therapy based on an emerging technology called optogenetics. If successful, the therapy will create light-sensing cells in one of her eyes and enable her to see again.

This patient and others being recruited for a clinical trial have a degenerative disease called retinitis pigmentosa. In this disease, the light-sensitive cells of the retina gradually die off. These cells pass electrical signals on to nerves that convey them to the brain.

The therapy uses optogenetics, a technology that uses a combination of gene therapy and light to precisely control nerves. The therapy should make certain nerve cells in the woman’s eye, called ganglion cells, light-sensitive. The eye was injected with viruses carrying DNA from light-sensitive algae. If it works, the cells will do what the healthy retina’s cones and rods do: fire off an electrical signal in response to light, restoring some vision.

Read more...

Image via Wikimedia